Lung cancer vaccine Tedopi official announced OS results mystery lifted.

Wen: The era of cake medicine is progressing, chemotherapy, targeted drugs, immunotherapy three anti-cancer drugs have come out, many difficult tumors are also broken one by one.
with the development of tumor genomics, biocell therapy has become a new method of tumor therapy, one of which is the high-profile tumor vaccine.
April 1, 2020, the tumor vaccine Tedopi tested positive in a Phase III clinical trial of NSCLC (non-small cell lung cancer), with a 1-year survival rate of 46% for backline therapy! More than 25% of the preset.
included are patients who have previously failed PD1/PDL1 treatment! Five months later, Tedopi's Phase III clinical study, Atlante-1, officially announced the final OS results, and the mystery was finally lifted. the
study included patients with advanced non-small cell lung cancer who had previously failed platinum chemotherapy and/or immunotherapy, who were 2:1 positive for blood HLA-A2, and were randomly grouped into OSE2101 (Tedopi) or standard treatment groups (dositamine or peso) as 2 or 3 lines of treatment, with the main study ending with OS.
the first major study endpoint was set to the OS rate of the experimental group for 1 year.
all patients were people with progress in PD1/PDL1 immunotherapy, with 11 per cent of patients using immunity, 87 per cent of patients using immunity on the second line and 2 per cent of patients using immunity on the third line.
study found that 29 of the 63 patients in the Tedopi group had a survival rate of at least 12 months and a one-year survival rate of 46 percent, up from 25 percent previously prescribed.
the 46 per cent survival rate observed in the programme was also higher than the 40 per cent survival rate assumed in the alternative effect hypothesis in the programme.
in the chemotherapy control group, 13 out of 36 patients survived for at least 12 months, with a one-year survival rate of 36%.
increased by 10%! 2, the mid-life OSTedopi group vs standard treatment group mOS: 9.8 months: 8.7 months, HR s 0.71, P s 0.17, decreased the risk of death by 29%.
report on the results, many researchers think it is very promising.
because the study was a single-drug treatment, not a combination of options, and because immunotherapy progression and even second-line, third-line drugs after chemotherapy progressed, there is still a trend of benefit to support further research on the vaccine.
follow-up research has shifted to vaccine-combined other treatments.
Previous studies showed very good data on the vaccine in previous Phase II clinical trials, with 64 HLA-A2-positive NSCLC patients in the group: 92% failed platinum chemotherapy, 34% failed targeted treatment, 67% received phase IV NSCLC; 66% received third-line systemic therapy; and 9% had brain metastasis.
From the patient characteristics, it can be seen that all patients in the group are terminal patients who have no available treatment options after the failure of standard treatment, after receiving Tedopi treatment, the total survival of the middle (OS) reached 17.3 months, and safety is controllable.
tumor vaccine is a novel treatment in tumor immunotherapy, it can identify the presence of proteins on specific tumor cells, can prevent tumor cell growth, prevent tumor recurrence, remove residual tumor cells after treatment.
Tumor vaccine activates or strengthens the body's autoimmune to tumor by expressing specific, immunogenic tumor antigens (e.g. peptides, DNA, RNA, etc.), assisted by adverbants such as cytokines and peptides, and so on, to kill and remove tumor cells.
the world's obsession with "tumor vaccines" has not subsided since the world's cancer fight began to take hold.
Tedopi findings offer new hope for patients with advanced NSCLC after immunosuppressant therapy fails, and Tedopi ® is now patented and the FDA has granted it HLA-A2-positive NSCLC orphan status.
not only works for the NSCLC, but the new face of the cancer vaccine community is about to begin challenging the "king of cancer" pancreatic cancer.
, OSE Immunotherapeutics is working with Shishi Shiguibo, a Phase II trial called TEDOPaM that will comprehensively evaluate the performance of the Tedopi® vaccine as a maintenance treatment, and the study will use Tedopi® Using the vaccine alone or in combination with Opdivo®, we look forward to evaluating whether it can bring greater survival benefits to pancreatic cancer patients compared to folfiri chemotherapy treatment for patients with stable HLA-A2 after 4 months of Folforinox standard chemotherapy.
: 1.;2.;3.;4.Gao J, Zheng Q, Xin N, Wang W, et al. CD155, an onco-immunologic products in human tumors. Cancer Science. 2017;108(10):1934-1938. doi: 10.1111/cas.13324.